Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| CIS Pharma | Pharma | 51.7% | 97th pct | 110 |
| Welfare International | Pharma | 31.6% | 75th pct | 110 |
| Gea | Pharma | 8.0% | 35th pct | 110 |
| Ivermedi | Pharma | -2.4% | 11th pct | 110 |
| Mermisi | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 4 of 5 peers filed FY2024. Switch to FY2023 (5 of 5).
| Ratio — FY 2024 | CIS Pharma | Gea | Ivermedi | Welfare International | Mermisi |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 62.3% | 36.4% | 21.9% | 39.9% | — |
| EBITDA Margin | 51.7% | 8.0% | -2.4% | 31.6% | — |
| EBITDAR | 34,062 | 3,681 | -1,095 | 12,762 | — |
| EBITDAR Margin | 51.7% | 8.0% | -2.4% | 31.7% | — |
| EBIT Margin | 51.2% | 7.3% | -2.4% | 31.6% | — |
| Net Profit Margin | 50.4% | 19.2% | -2.2% | 19.8% | — |
| Operating Expense % of Sales | 10.7% | 28.4% | 24.3% | 8.2% | — |
| Returns | |||||
| Return on Assets (ROA) | 62.9% | 17.7% | -2.6% | 32.3% | — |
| Return on Equity (ROE) | 101.5% | 23.5% | -3.2% | 89.6% | — |
| ROIC [EBIT / Invested Capital] | |||||
| 101.9% |
| 8.1% |
| -5.0% |
| 143.2% |
| — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 0.8% | 10.4% | 1.5% | 0.0% | — |
| Debt-to-Equity | 0.01x | 0.14x | 0.02x | 0.00x | — |
| Debt-to-EBITDA | 0.01x | 1.42x | N/A | 0.00x | — |
| Equity-to-Assets | 62.0% | 75.5% | 79.3% | 36.0% | — |
| Net Debt | 394 | 3,758 | -9,078 | -5 | — |
| Cash & Equivalents | 29 | 1,470 | 9,676 | 5 | — |
| Total Debt | 424 | 5,228 | 598 | N/A | — |
| Liquidity & working capital | |||||
| Current Ratio | 2.50x | 4.63x | 3.08x | 1.56x | — |
| Quick Ratio | 2.08x | 2.66x | 2.32x | 1.40x | — |
| Cash Ratio | 0.00x | 0.19x | 1.28x | 0.00x | — |
| Total Current Assets | 50,145 | 36,571 | 23,327 | 24,687 | — |
| Total Current Liabilities | 20,066 | 7,897 | 7,571 | 15,803 | — |
| Inventory | 8,323 | 15,569 | 5,779 | 2,570 | — |
| Trade Receivables | 41,790 | 18,650 | 5,888 | 22,109 | — |
| Trade Payables | 19,642 | 5,277 | 7,247 | 12,932 | — |
| Net Working Capital | 30,079 | 28,674 | 15,756 | 8,884 | — |
| Net Working Capital % of Revenue | 45.6% | 62.0% | 34.3% | 22.1% | — |
| Trade Working Capital | 30,471 | 28,941 | 4,420 | 11,747 | — |
| Trade Working Capital % of Revenue | 46.2% | 62.6% | 9.6% | 29.2% | — |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | — |
| Turnover & efficiency | |||||
| Inventory Turnover | 2.99x | 1.89x | 6.21x | 9.41x | — |
| Days Inventory Outstanding (DIO) | 122.2 | 193.2 | 58.8 | 38.8 | — |
| Receivables Turnover | 1.58x | 2.48x | 7.80x | 1.82x | — |
| Days Sales Outstanding (DSO) | 231.3 | 147.2 | 46.8 | 200.5 | — |
| Payables Turnover | 1.27x | 5.57x | 4.95x | 1.87x | — |
| Days Payable Outstanding (DPO) | 288.5 | 65.5 | 73.7 | 195.1 | — |
| Cash Conversion Cycle | 65.1 days | 274.9 days | 31.8 days | 44.2 days | — |
| Asset Turnover | 1.25x | 0.92x | 1.18x | 1.63x | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | 19,328 | 1,794 | 4,431 | 8,348 | — |
| Free Cash Flow (OCF − Capex proxy) | 18,473 | -3,454 | 3,318 | 8,416 | — |
| Cash Conversion (OCF / EBITDA) | 56.7% | 48.7% | N/A | 65.5% | — |
| Dividends Declared | 18,890 | 0 | 3,804 | 8,335 | — |
| Dividend Payout Ratio | 56.8% | 0.0% | N/A | 104.6% | — |